Zhejiang University: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Zhejiang University as lead sponsor. 10 are open to participants now and 0 have results posted.
Early Phase 1 9Phase 1 2Phase 2 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06793241Early Phase 1
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALLRecruitingNCT06633354Early Phase 1
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphomaRecruitingNCT06633341Early Phase 1
- CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHLRecruitingNCT06346912Early Phase 1
- Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing BlinatumomabRecruitingNCT06125106Phase 1
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLCompletedNCT04788472Phase 2
- Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALLStatus unknownNCT04740203Phase 1/2